Herman Kado, MD
Cardiovascular Disease · Southfield, MINPI 1033367362
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Inari Medical, Inc. accounts for 85.3% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2024 at $139,980 and has fallen 62.9% since, to $51,940 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 921 payments — averaging $479.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$377K
- Stryker$35K
- Angiodynamics, Inc.$12K
- Abbott$5K
- Amgen$1K
- Novartis$1K
- plus $10K from 54 others
Across 243 payments — averaging $1335.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$142K
- Imperative Care, Inc$142K
- Regeneron$41K
What the payments were for
- Consulting fees$181,91641%
- Speaking & faculty fees$212,47548%
- Travel & lodging$12,4813%
- Food & beverage$23,0645%
- Education$50%
- Other$12,0003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$406,191
- CT THROMBECTOMY SYSTEM KIT$401,983
- Auryon Laser System 100-120 Vac$12,000
- FlowTriever$5,377
- ClotTriever$5,275
- AMPLATZER AMULET$1,856
- Watchman$963
- ENSITE PRECISION$286
- AMPLATZER Occluders$264
- VERQUVO$253
- AMPLATZER$153
- Accent Pacemaker$148
- Confirm Rx$144
- SYMPHONY CATHETER$144
- Unify Assura CRT Defibrillator$144
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$133
- GORE CARDIOFORM Septal Occluder$129
- Inpefa$125
- CLOTTRIEVER BOLD CATHETER$105
- HeartMate 3 Left Ventricular Dev$103
How this compares
$441,941 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 537 | $600,104 |
| XareltoRivaroxaban | 419 | $476,121 |
| EntrestoSacubitril/Valsartan | 185 | $218,017 |
| MounjaroTirzepatide | 166 | $204,028 |
| OzempicSemaglutide | 190 | $182,993 |
| Repatha SureclickEvolocumab | 195 | $166,493 |
| JardianceEmpagliflozin | 99 | $99,464 |
| FarxigaDapagliflozin Propanediol | 78 | $70,847 |
| TrulicityDulaglutide | 44 | $51,915 |
| NexlizetBempedoic Acid/Ezetimibe | 62 | $44,133 |
| Praluent PenAlirocumab | 46 | $30,555 |
| Rosuvastatin Calcium | 1,214 | $22,186 |
| BrilintaTicagrelor | 20 | $22,115 |
| VerquvoVericiguat | 21 | $20,933 |
| VascepaIcosapent Ethyl | 29 | $16,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $358 | $600,104537 claims |
| Johnson & JohnsonXarelto | $852 | $476,121419 claims |
| Lilly USA, LLCMounjaro, Trulicity | $216 | $255,943210 claims |
| NovartisEntresto | $1,153 | $218,017185 claims |
| Novo NordiskOzempic, Rybelsus | $120 | $194,805201 claims |
| Boehringer IngelheimJardiance | $339 | $99,46499 claims |
| AstraZenecaFarxiga, Brilinta | $923 | $92,96198 claims |
| Esperion Therapeutics, Inc.Nexlizet | $681 | $44,13362 claims |
| MerckVerquvo | $1,061 | $20,93321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Southfield
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Douglas HorstmanshofRoyal Oak$407K
- David BachAnn Arbor$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.